Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Enzyme Targets
May 17, 2010
| A version of this story appeared in
Volume 88, Issue 20
The article on targeting the enzyme pyruvate kinase for cancer therapy is an interesting read (C&EN, Feb. 15, page 46). "Evaluation of Enzyme Inhibitors in Drug Discovery" (Wiley, 2005) states that enzyme targets are 47% of total targets in drug discovery-medicinal chemistry. Pharmaceutical scientists today refer to enzymes as the key to life. One could dream that pyruvate kinase is the answer to the dilemma in cancer research.
Hopefully, this old biochemical disease mechanism will help eradicate cancer. Sometimes, old mechanisms never die!
Mike Renier
South Range, Mich.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter